Review of DM1 treatment strategies outlines toxic RNA targeting and delivery challenges in muscle, heart, and brain
Therapeutic strategies targeting toxic RNA
A review of DNA- and RNA-targeted therapies for myotonic dystrophy type 1 (DM1) describes strategies to inhibit the production and activity of toxic RNA, along with challenges to clinical application. Key priorities include achieving efficient delivery to skeletal muscle, heart, and brain; ensuring long-term safety; and translating molecular correction into sustained clinical benefit. This paper is a literature review synthesizing findings from preclinical models and data from ongoing clinical trials, not a clinical trial providing new evidence of the efficacy of a specific treatment.
DM1 is the most common adult-onset muscular dystrophy. It is characterized by progressive muscle weakness and myotonia, cardiac conduction abnormalities, endocrine dysfunction, and central nervous system involvement. The review states that no curative treatment or disease-modifying therapy has yet been approved.
The cause is an abnormal expansion of CTG repeats in the 3′ untranslated region of the DMPK gene. The resulting expanded CUG-repeat RNA sequesters RNA-binding proteins, including Muscleblind-like proteins, and causes widespread alternative-splicing abnormalities. The central pathology is not simply a deficiency of DMPK function; it involves a toxic gain of function by the abnormal RNA.
Intervening at distinct points in DNA and RNA
DNA-level approaches include CRISPR-based genome editing. These strategies aim to reduce or remove the expanded CTG repeats or the DMPK allele carrying the expansion, thereby lowering toxic transcripts. This describes a development goal; the abstract alone cannot be interpreted as demonstrating genome correction and symptom improvement in patients.
At the RNA level, antisense oligonucleotides, small interfering RNA (siRNA), and microRNA-based tools such as antagomiRs are in development. The review also discusses antisense conjugates intended to improve delivery to skeletal and cardiac muscle. This highlights the need to assess both whether a therapeutic molecule can intervene in the disease process and whether it can reach the required tissues.
Other strategies described include using engineered RNA-binding proteins and decoy peptides to dismantle toxic RNA–protein aggregates. The review also covers an approach that selectively suppresses mutant DMPK by using a polyadenylation signal to terminate transcription early. Small molecules intended to modulate RNA metabolism, resolve CUG RNA aggregates, and correct abnormal splicing are also reviewed. These approaches target different points in the disease process, and the abstract provides no numerical data that allow direct comparisons of effects across candidates.
Turning molecular correction into sustained functional improvement
The challenges to clinical translation emphasized by the researchers are efficient delivery to skeletal muscle, heart, and brain; long-term safety; and reliable pharmacodynamic biomarkers. Indicators that a treatment has acted on its target biological process should be evaluated separately from evidence of sustained clinical benefit for patients. The researchers also identify combination and next-generation approaches as future opportunities.
The materials examined were the bibliographic information and abstract of a review published in an academic journal. They do not include individual trials’ patient characteristics, comparator groups, endpoints, effect sizes, follow-up durations, or detailed results by clinical development stage. Therefore, it is not possible to generalize that genome editing and RNA therapies are all at the same stage of development or that they prevent muscle weakness and cardiac complications. For a detailed overview, see the abstract of the review of therapeutic strategies targeting the molecular pathogenesis of DM1 in Molecular Diagnosis & Therapy.
Myotonic dystrophy type 1 is the most prevalent adult-onset muscular dystrophy and is characterized by progressive muscle weakness, myotonia, cardiac conduction defects, endocrine dysfunction, and central nervous system involvement. Myotonic dystrophy type 1 is caused by an unstable CTG repeat expansion in the 3' untranslated region of the DMPK gene, which produces toxic CUG-expanded transcripts that sequester RNA-binding proteins such as Muscleblind-like, induce widespread alternative splicing defects, and drive an RNA gain-of-function mechanism rather than simple DMPK haploinsufficiency. Despite major advances in understanding the molecular pathogenesis of myotonic dystrophy type 1, there is still no approved cure or disease-modifying therapy. This review summarizes the molecular basis of myotonic dystrophy type 1 and provides an in-depth overview of emerging therapeutic strategies that directly target the underlying pathogenic cascade at the DNA and RNA levels. Gene therapy-based approaches, including CRISPR-mediated genome editing, aim to reduce or eliminate the expanded CTG repeats or expanded DMPK allele and its toxic transcripts. In parallel, a broad spectrum of RNA-directed interventions is being developed, encompassing antisense oligonucleotides, antibody-penetrating and cell-penetrating peptide-conjugated antisense oligonucleotides to enhance skeletal and cardiac muscle delivery, small interfering RNAs, and microRNA-based tools such as antagomiRs. Additional strategies exploit engineered RNA-binding proteins and peptide decoys to disrupt toxic ribonuclear aggregates, polyadenylation signal-driven premature transcriptional termination to selectively silence mutant DMPK, and small molecules that modulate RNA metabolism, dissolve CUG RNA foci, or correct downstream mis-splicing. By integrating data from preclinical models and ongoing clinical trials, including recent advances with muscle‑targeted antisense oligonucleotide conjugates and gene therapy, this rev
This review organizes DM1 treatment candidates around shared disease mechanisms: toxic RNA and abnormal splicing. Bioscience researchers can consider where each candidate intervenes—at DNA, RNA, or interactions with RNA-binding proteins—and whether it can be delivered to the required tissues. Distinguishing molecular indicators of action on the target from sustained clinical benefit is especially useful when evaluating the evidence supporting development. However, the abstract provides no comparative numerical data on candidate efficacy or safety, so it is insufficient to judge the superiority of a particular technology or its likelihood of clinical success.